v3 Template
V

Vaxart, Inc.

Biotechnology South San Francisco, Calif., United States ~320 employees
Founded
--
Employees (Est.)
~320
16 leaders known
Total Funding
$74.3M
Funding Rounds
4
Last Funding
2024-06-13

About Vaxart, Inc.

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant pill vaccines using an innovative delivery platform. Their mission is to transform global health by pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases, aiming to create safe, effective, and accessible solutions to protect communities worldwide.

Products & Services

Oral Pill Vaccines:Vaccines delivered via oral pills designed to generate durable mucosal and systemic immunity, targeting diseases like COVID-19, Norovirus, Influenza, and HPV.
VAAST Platform:A proprietary technology platform used to develop and deliver oral recombinant vaccines.

Specialties

Oral Vaccine Development Mucosal Immunity Systemic Immunity Viral Disease Prevention

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Equity Offering
T: -
FT: Equity Offering 		A: 40000000
MR: -
FA: $40 million
FAN: 40000000 		D: 2024-06-13
FD: 2024-06-13 		1 investors
2 RT: Government Contract
T: -
FT: Government Contract 		A: 9270000
MR: -
FA: $9.27 million
FAN: 9270000 		D: 2024-01-19
FD: 2024-01-19 		1 investors
3 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering 		A: 10000000
MR: -
FA: 10.0 million
FAN: 10000000 		D: 2024-01-16
FD: 2024-01-16 		1 investors
4 RT: Public Offering
T: -
FT: Public Offering 		A: 15000000
MR: -
FA: $15,000,000
FAN: 15000000 		D: 2023-06-07
FD: 2023-06-07 		1 investors
Equity Offering Latest
2024-06-13
$40.0M
1 investor (Pro only)
Government Contract 2024-01-19
$9.3M
Registered Direct Offering 2024-01-16
$10.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

S

Steven Lo

Chief Executive Officer

LinkedIn (Pro only)
S

Sean Tucker, Ph.D.

Senior Vice President and Chief Scientific Officer

LinkedIn (Pro only)
J

James F. Cummings, M.D.

Chief Medical Officer

LinkedIn (Pro only)
R

Raymond D. Stapleton, Jr., Ph.D.

Chief Technology Officer

J

Jeroen Grasman

Chief Financial Officer

E

Edward B. Berg

Senior Vice President and General Counsel

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

Vaxart, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Website
vaxart.com
Industries
Biotechnology
Company Size
~320 employees (est.)
Locations
South San Francisco, Calif., United States
South San Francisco, Calif.

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro